We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$138M
AUM Growth
-$38.4M
Cap. Flow
-$16.8M
Cap. Flow %
-12.15%
Top 10 Hldgs %
98.27%
Holding
12
New
1
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.2M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$16M
2
KYNB
Kyntra Bio
KYNB
+$9.21M
3
PVLA
Palvella Therapeutics
PVLA
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 73.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$46.5M 33.65%
2,600,410
– –
JUNO
2
DELISTED
Juno Therapeutics, Inc.
JUNO
$34.4M 24.9%
753,564
-321,048
-30% -$16M
SNNA
3
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$13.8M 9.96%
758,610
– –
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.76M 7.06%
+1,000,000
New +$10.2M
JNCE
5
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7.39M 5.34%
579,650
– –
PVLA
6
Palvella Therapeutics
PVLA
$1.98B
$6.83M 4.94%
11,301
-3,750
-25% -$1.74M
KYNB
7
Kyntra Bio
KYNB
$28.5M
$6.19M 4.48%
5,226
-7,348
-58% -$9.21M
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$5.07M 3.67%
551,477
– –
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$3.03M 2.19%
22,248
– –
EGLT
10
DELISTED
Egalet Corporation
EGLT
$2.89M 2.09%
2,889,926
– –
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.02M 1.46%
223,457
– –
EPIX
12
DELISTED
ESSA Pharma
EPIX
$373K 0.27%
84,848
– –

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2017 Portfolio in Review

As of Q4 2017, Omega Fund Management held 12 positions worth $138M, down 22% from $177M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Omega Fund Management withdrew a net $16.8M in Q4 2017, reducing 3 holdings. Its largest reduction was Juno Therapeutics, Inc., cutting an estimated $16M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier.

Against the trend, Omega Fund Management opened a new position in ObsEva SA Ordinary Shares worth $9.76M.

  • Omega Fund Management's largest Q4 2017 buy was ObsEva SA Ordinary Shares: 1,000,000 shares worth $9.76M.
  • Omega Fund Management's biggest Q4 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $16M.
  • Omega Fund Management's ten largest holdings make up 98% of its $138M portfolio in Q4 2017.
  • Omega Fund Management opened 1 new position and closed 0 in Q4 2017.
  • Omega Fund Management's portfolio value fell 22% quarter-over-quarter to $138M.

Based on Omega Fund Management's 13F filing for Q4 2017, filed 5 Feb 2018.